Mallepally N, et al. - In this retrospective study at a tertiary care cancer center, researchers analyzed the clinical, endoscopic, and histologic characteristics of rituximab-associated colitis (RC). They excluded patients with competing etiologies for colitis. Of 13,717 patients treated with rituximab, RC was seen in 70 (4%). The median time of 181 days was reported for RC onset after rituximab treatment. Clinical gastrointestinal symptoms were reported in 53 patients, with diarrhea in 39, abdominal pain in 19, blood per rectum in 11, and a concurrent fever in 5. Mucosal ulceration on endoscopy and features of active inflammation on histology were seen in 9 patients and 52 patients, respectively. Based on the findings, RC was recognized as a usually mild disease that needs supportive care only, though colonic perforation and need for intensive care admission is seen on rare occasions with severe RC. RC severity can be hampered by using steroids with the chemotherapeutic regimen.